AACR Immediate Past President Antoni Ribas, MD, PhD, FAACR, and Gilbert S. Omenn, MD, PhD, moderated a panel focused on COVID-19 vaccine confidence.
(Clockwise, from top left) Sergio Quezada, PhD, Michel Sadelain, MD, PhD, Ignacio Melero. MD, PhD, and Anjana Rao, PhD, discussed approaches to developing new immunotherapies.
(Clockwise, from top left) Olufunmilayo I. Olopade, MD, FAACR, Tony Hunter, PhD, FAACR, Dennis J. Slamon, MD, PhD, FAACR, and William George Kaelin Jr., MD, FAACR, were the presenters.
(Clockwise, from top left) Luis Carvajal-Carmona, PhD, Tiffany Wallace, PhD, Nicole Coggins, PhD, Nora M. Navone, MD, PhD, and Kevin L. Gardner, PhD, took part.
Investigators in three related sessions shared details about 12 small molecules and biologics in or about to be tested in phase I clinical trials.
Antoni Ribas, MD, PhD, FAACR, discussed how researchers are working to change the treatment paradigm for patients with melanoma and reflected on his term as AACR President.
Presenters were (clockwise, from top left): Zhijan Chen, PhD, Mark Dawson, MD, PhD, Melissa Davis, PhD, Karen Vousden, PhD, FAACR, Matthew Vander Heiden, MD, PhD, and Jonathan Weissman, PhD.
(Clockwise, top left) Lipika Goyal, MD, Vivek Subbiah, MD, Jeffrey Goh, MBBS, and Jermaine Coward, MBBS, PhD, presented during the Annual Meeting’s last Clinical Trials Plenary session.
(Clockwise, top left) Samuel F. Bakhoum, MD, PhD, Karlene A. Cimprich, PhD, Stephen P. Jackson, PhD, and David Pellman, PhD, discussed its viability as a novel therapy target.
Updates on phase III trials came from (clockwise, top left) Matthew J. Matasar, MD, Jessica Hassel, MD, Patrick M. Forde, MBBCh, and Georgina V. Long, PhD, MBBS.
Subscribe below to get email updates from AACRMeetingNews.org